Shares of Hims & Hers Health (NYSE: HIMS) are falling on Friday. The company's stock lost 23.2% as of 1 p.m. ET and lost as ...

GLP-1 drugs like Wegovy and Ozempic, which are made by Novo Nordisk (NVO), have seen a shortage since 2022 amid rising demand. While that shortage was in effect, it allowed compounders - drug makers ...

The telehealth company has been selling a copycat version of a popular obesity drug during the recent shortage.

Shares of obesity-drug maker Novo Nordisk rose Friday after the Food and Drug Administration declared that the company’s popular medications Ozempic and Wegovy were no longer in shortage. A shortage o ...

Hims & Hers Health, Inc. (NYSE:HIMS) announced the acquisition of a California-based peptide facility to enhance its domestic ...

The Food and Drug Administration said on Friday that the shortage of semaglutide injection products, such as Novo Nordisk's Wegovy, has been resolved. FDA's update led to renewed uncertainty for a ...

Healthcare stock Hims and Hers (HIMS) is sharply lower today but has contrarian potential next week ahead of earnings ...

HIMS stock plunged by 18% after the FDA news that resolved a shortage of weight-loss drugs like Ozempic and Wegovy, which ...

Shares tumbled 21% to $52.22. Over the last year, the stock has surged more than 450%.

The massive crash came after the US Food and Drug Administration (FDA) website showed the end of the shortage of Novo Nordisk ...

It should be noted that Hims and Hers stock had jumped 43% in the week prior to the announcement, which has been attributed to the acquisition of Tybre Labs and a controversial Super Bowl ad.

The FDA just slammed the door on its booming weight-loss drug business--but Hims & Hers has a bold new strategy.